DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.10.19	DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs (GlobeNewswire)
09.10.19	DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (GlobeNewswire)
08.10.19	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position (GlobeNewswire)
04.10.19	DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy (GlobeNewswire)
02.10.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
19.09.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
07.08.19	DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy (GlobeNewswire)
01.08.19	DBV Technologies Reports First Half 2019 Financial Results (GlobeNewswire)
30.07.19	Ausblick: DBV TECHNOLOGIES mit Zahlen zum abgelaufenen Quartal (finanzen.net)
18.07.19	Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report (GlobeNewswire)
12.07.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
26.06.19	DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer (GlobeNewswire)
11.06.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
03.06.19	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
01.06.19	DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 (GlobeNewswire)
24.05.19	DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors (GlobeNewswire)
14.05.19	DBV Technologies Announces Departure of Deputy CEO David Schilansky (GlobeNewswire)
06.05.19	Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting (GlobeNewswire)
02.05.19	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
30.04.19	DBV Technologies Reports March 31, 2019 Cash Position (GlobeNewswire)
10.04.19	Information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
08.04.19	DBV Technologies Announces Closing of Global Offering (GlobeNewswire)
08.04.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
05.04.19	DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary S (GlobeNewswire)
04.04.19	DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (GlobeNewswire)
03.04.19	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares (GlobeNewswire)
01.04.19	DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F (GlobeNewswire)
06.03.19	Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
05.03.19	DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update (GlobeNewswire)
05.03.19	DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors (GlobeNewswire)
03.03.19	Ausblick: DBV TECHNOLOGIES vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
01.03.19	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
22.02.19	DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association (GlobeNewswire)
13.02.19	DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age (GlobeNewswire)
08.02.19	DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company (GlobeNewswire)
04.02.19	DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 (GlobeNewswire)
01.02.19	DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference (GlobeNewswire)
03.01.19	DBV Technologies Expands and Strengthens Leadership Team (GlobeNewswire)
19.12.18	DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age (GlobeNewswire)
12.12.18	DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018 (GlobeNewswire)
20.11.18	DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children (GlobeNewswire)
16.11.18	DBV Technologies Appoints Daniel Tassé as Chief Executive Officer (GlobeNewswire)
09.11.18	DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting (GlobeNewswire)
30.10.18	DBV Technologies Reports September 30, 2018 Cash Position (GlobeNewswire)
26.10.18	DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers (GlobeNewswire)
22.10.18	DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration (GlobeNewswire)
25.09.18	DBV Technologies to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
12.09.18	DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers (GlobeNewswire)
07.09.18	DBV Technologies : Reports First Half 2018 Financial Results (GlobeNewswire)
05.09.18	DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten